Search

According to Neil Rollings and Laurent Warlouzet, the historical analysis of the European competition policy has been a priority in the research on institutions but the reaction of companies to these policies has received less attention. This study highlights the importance of analyzing how public policies affect business strategies in innovation. More specifically, how the policy adopted by the High Authority of the ECSC regarding the scrap market influenced the strategies implemented by the steelmakers in the innovation of their production processes. The High Authority banned exports and established maximum prices and a system to equalise internal prices with import prices. This policy was considered a success by both institutions and companies. It decisively influenced the scrap price to be maintained at affordable levels in Europe. But this success in resolving the scrap problem created a larger one as it delayed innovation. This was the scrap paradox suffered by Europe. [ABSTRACT FROM AUTHOR]

Favoring innovation by making timely medical technology available to people and by securing patients' safety is a challenge. The new European Medical Device Regulation (MDR) will have a central implication in the development of new devices and could affect their innovation and availability, as well as discourage investment in research within Europe. Start-ups and small companies might not be able to cope with the increasing complexity and the required changes of perspective. Health-care institutions are facing an increasing availability of complex technologies, while data on their clinical efficacy and cost-effectiveness are rarely provided. A partnership/collaboration between health-care institutions, academia, and private industries will enhance their own specific interests with the common goal of improving overall health and quality of life. The complexity of the subject combined with the variety of specialists and stakeholders involved requires the implementation, in hospital centers of clinical excellence, of units dedicated to the whole path of the medical device innovation. Stakeholders should quickly provide adequate measures to facilitate the complex medical device innovation path under the more stringent MDR aimed to increase safety and quality of care. [ABSTRACT FROM AUTHOR]